Praluent Cardiometabolic Specialist Downsized / Leadership Screw-job

Quote

Who's Jimmy, Carolyn and Chainsaw saving?

  • Dumb women with hooters

    Votes: 0 0.0%

  • Xtreme sports fans

    Votes: 0 0.0%
  • Total voters
    0
anonymous said:
You're a tool. It had nothing to do with the reps, ultimately it had to do with contracting. There is no way that Amgen can continue to give it away. The manage care contracting was awful. How many plans was Praluent "exclusive" but Repatha had double digit market share. Regeneron lost its opportunity when they relied on Sanofi to handle the manage care. If you talked to the AE's they were all worried about diabetes.
Click to expand...

better a tool than a fool, alas it’s all Sanofi in EU and Praluent is winning there so go argue those facts mr. excuse factory
 






anonymous said:
better a tool than a fool, alas it’s all Sanofi in EU and Praluent is winning there so go argue those facts mr. excuse factory
Click to expand...

You stupid fuck..every country has a formulary. Do think there's Blue Cross and Blue Shield of Luxemborg? Your knowledge of international managed care is epically moronic.
 






You can't compare Europe with US..totally different healthcare systems. Let's just agree that management from both companies had no clue what they were doing . Everything was knee jerk reactions to anything Amgen did. This was expected as Sanofi as they never launched a drug successfully on their own. Lantus , Plavix, Lovenox were all with partners. BMS controlled all the marketing for Plavix..lantus was Aventis and so was Lovenox. Regeneron had no clue on how to work cardiology..this was a perfect storm dooming the product for failure. The money wasted was criminal.
 






As soon as we said we were getting rid of all you hanger-ons our stock price went up, Regeneron’s annual spend for Praluent far exceeded DUPI and Eyelea, you were all a cash and morale suck -

regards,

BoD
 






anonymous said:
You must have been on the “leadership team” from your stupid comment.
You can’t look at one survey and use it to blame reps.
How about poor managed care covered, lack of co pay support for over a year,
Patent lawsuit, constant turnover in leadership, etc....
You think this might have had an affect on the survey?
Click to expand...


You should have sold the science. Copay cards are a crutch for people with no selling skills.
 






anonymous said:
Spoken like a true management lackey who had no clue what there doing. Just face it - you failed, Len failed miserably, you were out marketed from the get go by Amgen . You practiced reactionary marketing , fumbled constantly at every turn but yes... it's all the reps fault. Watching any of you leadership clowns on stage told us exactly we were in trouble with this group of management stooges.
Click to expand...

It is 100% because of all the ex GSK managers and employees.
 






anonymous said:
You can't compare Europe with US..totally different healthcare systems. Let's just agree that management from both companies had no clue what they were doing . Everything was knee jerk reactions to anything Amgen did. This was expected as Sanofi as they never launched a drug successfully on their own. Lantus , Plavix, Lovenox were all with partners. BMS controlled all the marketing for Plavix..lantus was Aventis and so was Lovenox. Regeneron had no clue on how to work cardiology..this was a perfect storm dooming the product for failure. The money wasted was criminal.
Click to expand...

Really they’re different? You miss the point - those products both compete in the EU, just like they do in the US, both regions had to deal with an injunction, just like here, both products had to deal with pricing and step edits. You know what’s different, 2 things, they’re winning there and there are 0 Regeneron reps. It’s that simple
 






anonymous said:
You can't compare Europe with US..totally different healthcare systems. Let's just agree that management from both companies had no clue what they were doing . Everything was knee jerk reactions to anything Amgen did. This was expected as Sanofi as they never launched a drug successfully on their own. Lantus , Plavix, Lovenox were all with partners. BMS controlled all the marketing for Plavix..lantus was Aventis and so was Lovenox. Regeneron had no clue on how to work cardiology..this was a perfect storm dooming the product for failure. The money wasted was criminal.
Click to expand...

Really they’re different? You miss the point - those products both compete in the EU, just like they do in the US, both regions had to deal with an injunction, just like here, both products had to deal with pricing and step edits. You know what’s different, 2 things, they’re winning there and there are 0 Regeneron reps. It’s that simple
 






anonymous said:
You can't compare Europe with US..totally different healthcare systems. Let's just agree that management from both companies had no clue what they were doing . Everything was knee jerk reactions to anything Amgen did. This was expected as Sanofi as they never launched a drug successfully on their own. Lantus , Plavix, Lovenox were all with partners. BMS controlled all the marketing for Plavix..lantus was Aventis and so was Lovenox. Regeneron had no clue on how to work cardiology..this was a perfect storm dooming the product for failure. The money wasted was criminal.
Click to expand...

yeah it’s different for both companies and both products, when you compare EU performance between those 2 products Praluent does well. pretty clear answer, failure was largely at the customer level, again - find a mirror, look into it and recognize what you see. Total failure
 






anonymous said:
You stupid fuck..every country has a formulary. Do think there's Blue Cross and Blue Shield of Luxemborg? Your knowledge of international managed care is epically moronic.
Click to expand...

there is no managed care in EU, it’s a single payer system and those systems have step edits and specialty exclusions just like the US. we contracted market by market based on favorable reimbursement environment, reference pricing comparators and how we staffed. we worked with EMA and country HTAs to demonstrate our economic value and in most cases contracted for patients at 110 or higher to gain broader access. yeah, I don’t know anything about it.
 






anonymous said:
You stupid fuck..every country has a formulary. Do think there's Blue Cross and Blue Shield of Luxemborg? Your knowledge of international managed care is epically moronic.
Click to expand...

Funny Luxembourg? Have you ever heard of BeNeLux and how drug pricing and reimbursement are contracted? Quick, tell us all of the reference pricing country’s in the EU? To South America? Middle East and Africa? Asia Pacific? Come on now bright bulb
 






anonymous said:
You stupid fuck..every country has a formulary. Do think there's Blue Cross and Blue Shield of Luxemborg? Your knowledge of international managed care is epically moronic.
Click to expand...

Yeah, you are about as bright as a small appliance bulb, you know what they call someone in your family with half a brain? Gifted. You know what they call someone who’s bright in your home? A visitor. Dumb as a box of rocks and a silly little bopper-boy
 
























Big inflection following our release of sales reps, I guess everyone knows how ineffective you all were? Scripts are up, coats are done and margins looking better! Thanks all for nothing and all your GRIT! When the tough got going your leader got going, he had no GRIT, he was a crybaby!!!

Kisses,
MM
 












anonymous said:
As soon as we said we were getting rid of all you hanger-ons our stock price went up, Regeneron’s annual spend for Praluent far exceeded DUPI and Eyelea, you were all a cash and morale suck -

regards,

BoD
Click to expand...

Yeah, it's great winning when there's no real competition in those markets. Just read an article that showed Novartis product is on the same trajectory as Eyelea was on at launch. Since you are the goose that laid the golden egg, just wait until you can't keep up with their ridiculous goals.

An don't forget, we got paid well to leave. A lot had opportunities to stay, but why not take a little well earned vacay, while you're out dealing with the hub and all the changes they've made and not told anyone about.
 






anonymous said:
This is funny, since rep displacement our NRx are actually up! You reps actually “retarded” our growth!!!!
Click to expand...

Actually the data confirms that sales were ramping up for Praluent and as you know the increase in NRX’s always lags real time reporting by a few weeks. And speaking of allocation of funds, the Praluent and Sanofi teams have been restricted for over two years on everything from lunches to speaker funds. Compounded by poor contract coverage and continual push back by the payers. Very insensitive of people that post here about the Praluent sales force being ineffective. This group worked far harder for every script that the divisions that have dupi, a drug that practically sells itself. Show some professional respect.
 












Top Bottom
Back
Quote